Pfizer Inc. $PFE Shares Acquired by Inscription Capital LLC

Inscription Capital LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 135.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 50,246 shares of the biopharmaceutical company’s stock after acquiring an additional 28,946 shares during the quarter. Inscription Capital LLC’s holdings in Pfizer were worth $1,280,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Live Oak Investment Partners acquired a new stake in shares of Pfizer during the third quarter worth $357,000. Americana Partners LLC lifted its position in Pfizer by 6.1% during the third quarter. Americana Partners LLC now owns 942,561 shares of the biopharmaceutical company’s stock worth $24,016,000 after buying an additional 54,220 shares during the period. Root Financial Partners LLC acquired a new stake in Pfizer in the 3rd quarter worth about $200,000. QTR Family Wealth LLC purchased a new stake in Pfizer in the 3rd quarter valued at about $275,000. Finally, Horizon Bancorp Inc. IN increased its stake in shares of Pfizer by 3.9% during the 3rd quarter. Horizon Bancorp Inc. IN now owns 69,186 shares of the biopharmaceutical company’s stock valued at $1,763,000 after acquiring an additional 2,614 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: License deal for Matrix‑M adjuvant could accelerate Pfizer’s vaccine programs and support pipeline expansion; this is a concrete R&D/capability win. Novavax enters license agreement with Pfizer for vaccine development
• Positive Sentiment: Recent quarterly results and FY‑2025 guidance (EPS range ~3.00–3.15) show profit generation and set expectations for the year, supporting baseline valuation (beat on EPS, mixed on revenue).
• Neutral Sentiment: JPMorgan conference takeaways highlight industry-wide themes — drug pricing pressure, looming patent cliffs, and dealmaking — that shape mid‑cycle expectations for big pharma including Pfizer. Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
• Neutral Sentiment: Analyst pieces compare Pfizer to peers (e.g., Eli Lilly) on growth outlook and product mix; these comparisons keep PFE under scrutiny but don’t change fundamentals immediately. Which Pharma Stock Stands Taller Right Now: LLY or PFE?
• Neutral Sentiment: Quarterly outlook notes (non‑oncology) — Eliquis strength vs softer COVID sales — imply mixed revenue drivers heading into the next report. What to Expect From Pfizer’s Non-Oncology Business in Q4?
• Neutral Sentiment: Thematic ETF/sector coverage pieces mention PFE exposure among obesity/GLP-1 and vaccine plays, which can attract longer‑term interest but provide limited near‑term price support. Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All (PFE)
• Negative Sentiment: CEO Albert Bourla said U.S. drug prices are coming down — investors interpret this as potential margin and top‑line pressure from pricing reform and negotiations. Pfizer CEO Albert Bourla: U.S. drug prices are coming down
• Negative Sentiment: Pfizer is exiting parts of the ViiV HIV joint venture as partners reshuffle stakes, reducing exposure to the JV’s future upside and simplifying the company footprint. Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture
• Negative Sentiment: Longer‑term skepticism persists (coverage pieces noting the stock is down materially from peak due to past trial failures and upcoming patent cliffs), which keeps valuation under pressure and can limit rebounds. Down 55%, Should You Buy the Dip on Pfizer?

Pfizer Trading Down 0.5%

Shares of PFE opened at $25.52 on Wednesday. The stock’s 50-day moving average is $25.38 and its two-hundred day moving average is $24.99. The stock has a market cap of $145.07 billion, a PE ratio of 14.83 and a beta of 0.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is 100.00%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on PFE. HSBC reissued a “buy” rating and issued a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. Scotiabank initiated coverage on Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price objective for the company. Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and issued a $26.00 price objective on shares of Pfizer in a research note on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $27.88.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.